About Clavis Pharma
Clavis Pharma is a company based in Oslo (Norway) founded in 2001 by Carlos Roig. It operates as a B2B. Clavis Pharma has completed 1 acquisition, including Aqualis Offshore. Clavis Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter Oslo, Norway
- Founders Carlos Roig
- SectorsHealthcare
- Website clavispharma.com
- Latest Funding Round$27.03M (USD), Post-IPO
Jan 2012
- InvestorsInnovasjon Norge
& 1 more
- Investments & Acquisitions
Funding Insights of Clavis Pharma
- Total Rounds 7
- Last Round Post-IPO — $27.03M
- First Round $20M
(Jun 2009)
- Investors Count 2
All 7 funding rounds of Clavis Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2012 | $27.03M | Post-IPO | – | – | – |
| Jun 2011 | $2.5M | Grant | – | – | |
| Dec 2010 | $25.58M | Post-IPO | – | – | – |
| Dec 2009 | $3.2M | Debt – Conventional | – | – | |
| Sep 2009 | $1.18M | Grant | – | – | |
| Aug 2009 | $1.1M | Grant | – | – | |
| Jun 2009 | $20M | Post-IPO | – | – | – |
2 investors in total: 2 institutional.
Investors in Clavis Pharma
Clavis Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Innovasjon Norge and Norwegian Research Council.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research policy advice is provided to the Norwegian government. | 1993 | forskningsradet.no | Oslo, Norway | |
Consulting services in agriculture, travel, and international investments are offered. | 2004 | innovasjonnorge.no | Oslo, Norway |
Investor details for Clavis Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Clavis Pharma
1 people are tracked at Clavis Pharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Carlos Roig | Founder | Leadership |
Complete people profiles for Clavis Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Clavis Pharma
Clavis Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Aqualis Offshore.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Offshore services firm founded in Norway in 2013. | aqualisoffshore.com | Norway | 2013 | Oct 2013 | $11.54M |
Complete acquisition details for Clavis Pharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Clavis Pharma
4 dated milestones of Clavis Pharma across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Clavis Pharma is founded.
- Funding First funding round of $20.0M.
- Funding Latest funding round, Post-IPO, of $27.0M.
- Acquisition Acquires Aqualis Offshore.
Competitors of Clavis Pharma
Clavis Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. |
Detailed competitors of Clavis Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Clavis Pharma
10 companies that operate in the same segment as Clavis Pharma (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Clavis Pharma
Clavis Pharma was founded in 2001 and raised its 1st funding round 8 years after it was founded.
Clavis Pharma is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
Clavis Pharma, established in 2001, excels in providing healthcare solutions, advancing biotech innovations, oncology therapeutics, and small molecule development. Develops innovative small molecule therapeutics for cancer treatment. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
Clavis Pharma's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Clavis Pharma has made 1 acquisition, including Aqualis Offshore.
Clavis Pharma has 2 investors. Key investors include Innovasjon Norge, and Norwegian Research Council.